Atlanta Biomedical

Executive Summary

Atlanta Biomedical, headquartered in Suwanee, Georgia, was founded in 2008 by industry veterans with over 130 years of combined experience in syringe pump technology. The company focuses on developing the most efficient and innovative syringe infusion pump for medication delivery. Its leadership team, including founders Bill Arthur III, Charles Lee, and Julius Stempfle, brings deep domain expertise to address unmet needs in infusion therapy, aiming to improve accuracy, safety, and workflow efficiency in clinical settings. While the company has remained private and has not disclosed funding or valuation details, its long-standing presence suggests steady progress in product development and market positioning. Looking ahead, Atlanta Biomedical is poised for potential catalysts that could accelerate its growth and market adoption. The company may seek FDA 510(k) clearance for its latest pump model, enabling commercial launch in the U.S. hospital market. Additionally, strategic partnerships with drug delivery or hospital supply chains could expand distribution. Finally, a Series A or B funding round might be pursued to scale manufacturing and sales efforts. With a focused product line and experienced team, Atlanta Biomedical is positioned to capture share in the competitive infusion pump market.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for New Syringe Infusion Pump70% success
• Q4 2026Strategic Partnership with Hospital System or Distributor50% success
• Q2 2027Series A/B Funding Round40% success